Investors including Peppermint Venture Partners and Creathor Ventures have committed €7m to cryotherapy treatment company CryoTherapeutics.
Peppermint Venture Partners is currently investing from its €31m Charité Biomedical Fund, which it had used to make investments in CryoTherapeutics previously.
Creathor is deploying its Creathor Venture III fund, which closed on €80m in 2012.
Other investors in the round include Belgian public investor Noshaq, the Walloon region and Getz Brothers. The funding consists of both equity and debt, as well as non-dilutive cash advances granted by the Walloon region.
The fresh capital will be used to support the company's clinical trials programme, to establish an operations facility in Awans, Belgium, and for talent acquisition.
In 2013, High-Tech Gründerfonds (HTGF) and Peppermint led a €3m investment round for the company with participation from NRW Bank.
Peppermint led a €3.5m extension funding round in 2014. HTGF, NRW, Rainer Christine Asset Management, Getz Brothers and new investor KfW also took part in the extension.
Creathor led a €5.2m series-B in 2016. Investors NRW, Peppermint, HTGF, Getz Brothers, KfW and business angels committed alongside the VC.
Founded in 2009, the company develops cryotherapy systems for the treatment of coronary artery disease, which causes heart attacks. Previously based in Cologne, the company is now based in Awans.
Peppermint Venture Partners – Joachim Rautter (managing partner).
Creathor Ventures – Karlheinz Schmelig (partner).
Noshaq – Joanna Tyrekidis (investment manager).
CryoTherapeutics – John Yianni (CEO).
Windhoist Holdings is Star Capital's sixth acquisition from its Strategic Assets III vehicle
Both Palatine Private Equity Fund III and IV used Evercore as their placement agent
GP deploys capital from its DBAG Fund VII, which held a final close on its €1bn hard-cap in 2016
Pemberton's most recent fundraise brings the direct lender's assets under management to €5.5bn